Age years (SD) | 63 (14) |
NYHA Class (n=14) | III | 7/14 (50%) |
| IV | 7/14 (50%) |
Race | Hispanic | 8/14 (57%) |
| Caucasian | 4/14 (29%) |
| Middle Eastren | 1/14 (7%) |
| Filipino | 1/14 (7%) |
Diffuse Lung Disease | Idiopathic Pulmonary Fibrosis (IPF) | 4 (29%) |
| NSIP fibrosis | 3 (21%) |
| Chronic Hypersensitivity Pneumonitis | 2 (14%) |
| Pulmonary Fibrosis, unknown | 1 (7%) |
| IPF/Emphysema (CPFE) | 4 (29%) |
Baseline Therapy (n) | Phosphodiesterase-5 Inhibitors (PDE5-I) | 5 |
| Endothelin Antagonists (ERA) | 3 |
| ERA/PDE5-I | 3 |
| None | 3 |